ItilTMItilKZQuantitative EEG brain mapping in psychotropic drug development, drug treatment selection, and monitoring. Am J Therapeutics1995;2:359–367.
2.
WuXXiaoCHQuantitative pharmaco-EEG of carbamazepine in volunteers and epileptics. Clin Electroencephalogr1996;27:40–45.
3.
WuXMaJJSodium valproate: Quantitative EEG and serum levels in volunteers and epileptics. Clin Electroencephalogr1993;24:93–99.
4.
OkajmaYKinoshitaISaitoAQuantitative pharmaco-EEG study of neurotropin. Asia Pacific J Pharmacology1987;2:13–18.
5.
GramLBentsenKDValproate: An updated review. Acta Neurol Scand1985;72:129–139.
6.
BruinvelsJvan der LaanIWValproic acid: Its mechanisms of action. In: ManelisJBentalELoeberJNDreifussFE (eds). Advances in Epileptology, Vol 17, New York: Raven Press; 1989: 153–156.
7.
RentmeesterTHHulsmanJ.Sustained release valproate: A study of the tolerance and efficacy of LA40220. In: ChadwickD (ed). Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy. International Congress and Symposium Series N152. London: Royal Society of Medicine; 1989: 185–191.
8.
SannitaWGGervasioLZagnoniP.Quantitative EEG effects and plasma concentration of sodium valproate: Acute and long-term administration to epileptic patients. Neuropsychobiology1989;22:231–235.
9.
SannitaWGBalstraVDiBonGHassanKMRosadiniG.Ammonia-independent modifications of the background EEG signal and paradoxical enhancement of epileptic abnormalities in EEG after acute administration of valproate to epileptic patients. Neuropharmacology1993;32:1–10.
10.
SannitaWGBalbiAGiacchinoFRoasdiniG.Quantitative EEG effects and drug plasma concentration of phenobarbital, 50 and 100 mg single-dose oral administration to healthy volunteers: Evidence of early CNS bioavailability. Neuropsychobiology1990–1991;23:205–212.
11.
HerkesGKLagerlundTDSharbroughFWEffects of antiepileptic drug treatment on the background frequency of EEGs in epileptic patients. J Clin Neurophysiol1993;10:210–216.
